Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact
  • Home
  • ›
  • Malignant Mesothelioma
  • ›
  • Treatment
  • ›
  • Clinical Trials
  • ›
  • VISTA Protein
Page Updated: January 31, 2022

VISTA Protein Clinical Trials

Kyle J. Becker Page Medically Reviewed and Edited by Kyle J. Becker, PharmD, MBA, BCOP

FREE Mesothelioma Packet

Fact Checked

This page has been fact checked by a Doctor of Pharmacy who specializes in Oncology. Sources of information are listed at the bottom of the article.

FREE Mesothelioma Packet

We make every attempt to keep our information accurate and up-to-date.

Please Contact Us with any questions or comments.

VISTA protein clinical trials are testing a drug known as CA-170 for its potential effectiveness as a type of cancer therapy. CA-170 is an immunotherapy drug that prevents the deactivation of immune system T-cells by the cancer cells. VISTA clinical trials need mesothelioma patients to participate.

FREE Mesothelioma Packet

Immune Checkpoint Proteins and Inhibitors

VISTA (V-domain Ig suppressor of T-cell activation) is a type of protein that helps cancer cells avoid attack by the body’s immune system. Immune system T-cells have proteins on their surfaces known as checkpoints. Other cells have proteins on their surfaces that interact with these checkpoints, turning them off and telling the immune cell not to attack. The VISTA clinical trial is the first to test a drug that targets this specific protein.

Although healthy cells have the specific proteins that bind to and disable checkpoints on T-cells, so do cancer cells. PD-1 is one example of a checkpoint protein targeted by new cancer therapies. T-cells have PD-1 on their outer surfaces. When PD-1 binds to a protein known as PD-L1 on other cells, it knows not to attack that cell.

Drugs that target either PD-1 or PD-L1 can potentially block the interaction between immune cells and cancer cells. This allows T-cells to go ahead and attack the tumor.

Another protein, known as VISTA, is similar to PD-L1.[1] VISTA is expressed by more than 90% of mesothelioma cancer cells, making it an excellent target for new therapies. If a drug can block VISTA, the immune system has a better chance of targeting the cancer cells.

CA-170

The new drug currently being tested in clinical trials is known as CA-170. Curis, Inc, a biotechnology company that focuses on cancer treatments, is developing and testing the drug. CA-170 is an immune checkpoint inhibitor that targets VISTA.[2]

CA-170 is new and unique in that it is the first therapy tested to target VISTA. Other checkpoint inhibitors that target PD-L1 have already been discovered and tested. Drugs like atezolizumab (Tecentriq) and durvalumab (Imfinzi) are proving to help the immune system to identify and fight cancer.

But CA-170 is the first new therapy that hypothesizes that it can target both PD-L1 and VISTA. The early stages of testing show promising results that this drug can help patients with non-small cell lung cancer. Everyone is interested to see how it works in mesothelioma.

VISTA Clinical Trials

The CA-170, VISTA, and PD-L1 phase I clinical trial is now complete. The trial was conducted in several locations, including San Francisco, California, and Denver, Colorado.[1] Even though this trial is no longer accepting participants, others will continue to open as the compound begins to show safety and efficacy.

Patients with mesothelioma began treatment with the drug in January 2019. The purposes of the phase I trial are to determine the drug’s clinical effects, how it works, and if it is safe. Mesothelioma patients were given two levels of doses administered every day for two twenty-one-day cycles.

Getting Involved in Clinical Trials

This is just one example of many ongoing clinical trials recruiting new patients with mesothelioma. Clinical trials not only test for effectiveness but also test the safety of new therapies. When deciding to participate in any clinical trial, it is important to weigh the risk of side effects. It is also essential for patients to understand that the outcome of these therapies may not be what they hope.

CA-170 is such a new drug that there are no currently known common side effects. Animal and laboratory studies cleared it as safe enough for human clinical trials; however, this does not mean this drug will be proven safe for human patients.

Clinical trials often have stringent inclusionary criteria to make sure suitable patients get a chance to participate. While every trial is different, examples of these criteria for inclusion in a CA-170 study are:

  • Be 18 years old or older
  • Have been given a life expectancy of three months or longer
  • Have adequate organ functioning and bone marrow
  • Be able to swallow oral medications
  • Have negative pregnancy test results
  • Have a measurable disease
  • Be diagnosed with a cancer that has high VISTA expression, like mesothelioma, or have a cancer not responding to standard therapy

If you are interested in learning more about the CA-170 and VISTA trials, talk to your oncologist or other members of your medical team. Mesothelioma patients often qualify for trials because of the aggressive nature of this cancer and how difficult it is to treat.

Get Your FREE Mesothelioma Packet

Page Medically Reviewed and Edited by Kyle J. Becker, PharmD, MBA, BCOP

Kyle J. Becker

Kyle J. Becker, PharmD is certified by the Board of Pharmacy Specialties in Oncology Pharmacy. Dr. Becker earned his pharmacy degree from Shenandoah University and he currently serves as an oncology pharmacist at Parkview Cancer Institute.

Connect with Oncology Pharmacist Kyle J. Becker
References
  1. Curis, Inc. (2020, June 26). A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients with Advanced Tumors and Lymphoma.
    Retrieved from: https://clinicaltrials.gov/ct2/show/study/NCT02812875
  2. Cision PR Newswire. (2019, January 24). First Mesothelioma Patient Dosed in CA-170 Study.
    Retrieved from: https://www.prnewswire.com/news-releases/first-mesothelioma-patient-dosed-in-ca-170-study-300783484.html
View All References

Site Navigation

Home
Malignant Mesothelioma
How to Survive Mesothelioma
100 Questions & Answers about Mesothelioma (Free Book)
Surviving Mesothelioma - Beating the Odds (Free Book)
FREE Mesothelioma Packet
Symptoms
Shortness of Breath
Cough
Night Sweats and Fever
Weight Loss
Pain
Difficulty Swallowing
Fatigue and Muscle Weakness
Gastrointestinal Complications
Diagnosis
Pathology
Staging
Stage 1
Stage 2
Stage 3
Stage 4
Metastasis and Progression
Brain Metastasis
Biopsy
miRview Test
Imaging
Fine Needle Aspiration Biopsy in Mesothelioma
Biomarkers and Blood Tests
Calretinin
Prognosis
Remission
Recurrence
Death Rate
Life Expectancy
Search for a Mesothelioma Cure
Types
Pleural
Peritoneal
Epithelioid
Sarcomatoid
Biphasic
Pericardial
Testicular
Cell Types
Rare Subtypes of Mesothelioma
Deciduoid
Desmoplastic
Heterologous
Lymphohistiocytoid
Well-Differentiated Papillary
Tubulopapillary
Small Cell
Benign
Adenomatoid
Cystic
Unresectable
Localized
Idiopathic
Omental
Causes
Risk Factors
Latest Research
Genetic Components
Incidence
Latency Period
Mesothelioma Tumor
Health Insurance Coverage
Related Conditions
Immunodeficiency Disorders
Cholangiocarcinoma
Atelectasis
Pleural Plaques
Pleural Thickening
Pleural Effusion
Peritoneal Effusion (Ascites)
Mesothelial Hyperplasia and Proliferation
Pleuritis and Pleurisy
COPD
Anemia
Breast Cancer
Prevention
Complications
Misdiagnosis
Mesothelioma Commercial
Talcum Baby Powder
Lawyer
Lawsuits
Class Action Lawsuits
Settlements
Simian Virus 40
Differences From Other Cancers
Lung Cancer
Women
Children and Young Adults
Unknown Asbestos Exposure
Mesothelioma Without Asbestos
Cause of Death
Facts 
History
Awareness
Government and Research
National Mesothelioma Virtual Bank
Support
What to Expect
Living with Mesothelioma
Help a Loved One
Wrong and Right Things to Say
Caregivers
Financial Tips
Faith
Nutrition and Lifestyle
Intimacy
Mesothelioma and Fertility in Men
Fertility in Women with Mesothelioma
Emotional Health
COVID-19
Assisted Living
Hospice Care
Dying from Mesothelioma
Mourning
Coping Guide for Children
End-of-Life Decisions
Mesothelioma Awareness Day
Compensation for Victims
Lawyer
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington D.C.
Washington
West Virginia
Wisconsin
Wyoming
Lawsuit
Settlements
Statute of Limitations
Treatment
Surgery
Side Effects
Pneumonectomy
Extrapleural Pneumonectomy
Lobectomy
Pleurectomy/Decortication
Post Op Care
Pleurectomy/Decortication vs. Extrapleural Pneumonectomy
Peritonectomy/Cytoreductive Surgery
Thoracotomy
Thoracoscopy
Pericardiectomy
Wedge Resection
Pleurodesis
Pericardiocentesis
Prosthetics
Paracentesis
Thoracentesis
Chemotherapy
Side Effects
Heated Intraperitoneal
Radiation Therapy
Side Effects
Intensity-Modulated
Brachytherapy
Proton Therapy
Image-Guided
External Beam
Three-Dimensional
Multimodal Therapy
New Treatments
SMART Protocol
Gene Therapy
Suicide Gene Therapy
Tumor-Based p53 Therapy
Cryotherapy for Mesothelioma
Tumor Treating Fields
MicroRNA
Palliative Treatment
Osteopathic
Doctors
Treatment Centers
Treatment & Doctors Near You
Mesothelioma Experts
Medications
Alimta (pemetrexed)
Adriamycin (doxorubicin)
Avastin (bevacizumab)
Cytoxan (cyclophosphamide)
Gemzar (gemcitabine)
Keytruda (Pembrolizumab)
Mitomycin
Navelbine (vinorelbine)
Opdivo (nivolumab) and Yervoy (ipilimumab)
Paraplatin (carboplatin)
Platinol (cisplatin)
Rheumatrex (methotrexate)
Sutent (sunitinib)
Taxol (paclitaxel)
Medical Marijuana
Care Providers
Clinical Trials
Anetumab Ravtansine
Atezolizumab
Chimeric Antigen Receptor (CAR) T-Cell
Durvalumab
Immunotoxin
Interferon Alfa-2b
Onconase (Ranpirnase)
VISTA Protein
Costs
Immunotherapy
Nanotechnology
Hyperbaric Oxygen Therapy
Home Medical Equipment
HMGB1 Secretion
Photodynamic Therapy
Targeted Therapies
Apoptosis
Stem Cells
Lung Transplantation
Body-Based Therapies
Alternative Therapies
Paul Kraus’s Method
Doctors and Treatment in Canada
Asbestos Trusts
Veterans
VA Claims for Mesothelioma
Vietnam Veterans
Military Branches and Asbestos
Navy Veterans
Navy Ships
Aircraft Carriers
Battleships
Destroyers
Asbestos on Navy Cruisers
Submarines
Amphibious Ships
Minesweepers
Auxiliary Ships
Marine Corps Veterans
Army Veterans
Air Force Veterans
U.S. Coast Guard
Asbestos
Occupational Exposure
Construction Workers
Shipyard Workers
Ship Repair
Steel Mill Workers
Industrial Workers
Boiler Workers
Power Plant Workers
Firefighters
Automotive Workers
Roofers
Oil Refineries
Mining
Transportation Industry
Machine Operators
Farmers and Agricultural Workers
Migrant Workers
Electrical Wiring
Labor Unions
Prisons
Chimneys, Furnaces, and Wood Stoves
Fiberglass Connection to Mesothelioma
Home Remodeling
School Buildings, Teachers
For Tech Students
Cancer
Lung Cancer
Pleural Based Cancers
Ovarian Cancer
Ovarian Cancer Lawsuits
Companies That Used Asbestos
Awareness and Education
Types of Asbestos & Mesothelioma Risk
Asbestosis
Interstitial Lung Disease
Smoking
Asbestos Ingestion
Exposure in a Natural Disaster
Ban Asbestos
Libby, Montana
Recycling Asbestos
Asbestos Detection
Legal Information by State
Canada
Mexico
United Kingdom
Australia
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net